Søgning


Flere søgeindstillinger

Søgning på udtrykket 'tuber' giver 63 resultater


Dokumenter [11] Sider [5] Kalender [1] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
Dokumenter [11]

Denne vejledning omhandler vurdering og behandling af tuberkuloseinfektion hos voksne, som skal behandles med immunsupprimerende medicin i form af f.eks TNF-α hæmmere eller andre immunsupprimerende biologiske lægemidler, hvor der er øget risiko for tuberkulosereaktivering. Guideline dækker ikke børn, personer med medfødt immundefekt, HIV positive, patienter i dialyse, patienter med dysreguleret diabetes, silicose, erhvervede immundefekter eller patienter i konventionel kortvarig kemoterapi. Denne g.

Denne vejledning omhandler diagnostik og behandling af voksne med TB, herunder pulmonal- og ekstrapulmonal-TB samt antibiotika-resistent TB. For håndtering af infektioner forårsaget af andre mykobakterier henvises til anden litteratur. 26.09.23: Moxifloxacin varighed ændret til 8 uger (tabel 10)

Omhandler biologiske og målrettede syntetiske lægemidler (BMSL) til patienter i forhold til risiko for tuberkulose (TB), Humant Papillom Virus (HPV), Hepatitis B og C (HBV og HCV), Varicella Zoster Virus (VZV), Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) og Humant Immundefekt Virus (HIV) og øvrige infektioner. Vejledningen er udarbejdet af repræsentanter fra Dansk Selskab for Gastroenterologi og Hepatologi (DSGH), Dansk Reumatologisk Selskab (DRS), Dansk Dermatologisk Se.

Udarbejdet af en arbejdsgrupper bestående af medlemmer fra Dansk Selskab for Infektionsmedicin og Dansk Transplantationsselskab

Møde for yngre infektionsmedicinere. Overlæge dr. med. Troels Lillebæk fortæller om diagnostik og behandling af tuberkulose.

Skema til registerering af diagnostik, behandling og respons

Despite available guidelines for œstandardized treatment of drug sensitive and drug resistant tuberculosis, the clinician is often faced with cases not solved by standard recipes. During this master class, we will discuss clinical cases. We invite the participants to submit difficult and/or interesting clinical cases that will be the focus of the day.

Heldagsmøde i København

Sider [5]

…ag, såvel før som efter identifikation af udløsende mikroorganisme, Vurdere behovet for anden intervention end antibiotika, Kritisk kunne vurdere videnskabelige artikler med infektionsmedicinsk indhold, Herudover at give kursisterne en viden om tuberkulose, diagnostik og behandling, så de selvstændigt kan varetage udredning og behandling af patienten med tuberkulose eller anden mykobakteriel infektion.

…emedicin: Peter Ellekvist (tovholder), Anders Porskrog, Carsten Schade Larsen, Fredrikke Christie Knudtzen, Kim Peter David, Lasse Skafte Vestergaard, Marie Helleberg, Mike Zangenberg, Sanne Jespersen, Signe Mai Sørensen Malaria (2019), Tuberkulose: Isik Somuncu Johansen (tovholder), Pernille Ravn, Christian Morberg Wejse, Ole Kirk, Michael Dalager-Pedersen, Troels Lillebæk og Mike Zangenberg Tuberkulose - diagnostik og behandling (2023), Vaccinationer: Zitta Barrella.

…rsus. 2027: Program. Afventer Sted. Hvidovre Hospital Delkursusledelse. Rikke Krogh-Madsen og Michael Dalager-Pedersen Tidligere kurser. 11. og 12. juni 2024 8. og 9. juni 2021 15. og 16. maj 2018 Kardiopulmonale infektioner og tuberkulose: Næste kursus 2026: Delkursusledelse. Michala Vaaben Rose, Stig Lønberg og Andreas Knudsen Tidligere kurser. 29. og 30. marts 2023 28. og 29.

… et al: Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial. PLOS ONE. 2009;4(5):e5575. Abdool Karim et al: SS1, Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011 Oct 20;365(16):1492-501 (samt ACTG5221 og CAMELIA studierne i samme nummer af NEJM). HPV og HIV:.

Professor Åse Bengaard Andersen kommenterer: Læs ikke denne artikel - med mindre du har særlig tuberkulose interesse. Men hvem har ikke det i vores selskab? 'Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis' af Feng Sun og kolleger publiceret i Antimicrobial Agents and Chemotherapy - et retrospektivt studie fra Kina, der antyder at Linezolid kan give et godt bidrag til behandling af tuberkuløs meningitis.

…Isik Somuncu Johansen kommenterer: Et trist resultat: I 2013 rapporterede Ruslami et al. (Lancet Infect Dis. 2013 Jan;13(1):27-35) nedsat mortalitet ved IV administrering af en øget dosis Rifampicin og Moxifloxacin i blot 14 dage til ca. 60 patienter med tuberkuløs meningitis - efterfulgt af standard behandling. Der var derfor store forventninger til denne store kliniske trial, hvor effekten af øget Rifampicin dosis samt et flourquinolon (per oralt) blev undersøgt på ca. 700 Vietnamesiske patienter.

Professor Troels Lillebæk kommenterer: Et studie som foranlediger, at vi skal til at skrive lærebøgerne om. I to årtier har WHO på baggrund af Mantoux-test skønnet, at ca. en tredjedel af jordens befolkning er inficeret med Mycobacterium tuberculosis. Det nye skøn fra den nordiske forfattergruppe, som for nylig er publiceret i European Respiratory Journal, nedjusterer det til knap en fjerdedel af jordens befolkning. Dette svarer også til WHO's seneste skøn fra 2016.

Professor Troels Lillebæk kommenterer: I denne Nature Communications artikel beskrives det hvordan det, for første gang nogensinde, er lykkedes at inducere en længerevarende effekt af en tuberkulose vaccine ved at kombinere gammelkendte BCG med 8 antigener i en subunitvaccine. Efter min mening det mest lovende tuberkulosevaccineforsøg til dato, som giver håb om en effektiv vaccine i fremtiden.

Professor Troels Lillebæk kommenterer: Er fødevarer den effektive effektive TB-vaccine vi allerede har? I dette - ifølge forfatterne - første randomiserede forsøg, der ser på effekten af ernæringsstøtte på tuberkuloseforekomsten i husholdningskontakter ses en ganske væsentlig (39-48%) reduktion i tuberkuloseforekomsten i husstanden i løbet af 2 års efterfølgelse! Måske er der en parallel til det der skete i Danmark i første halvdel af det 20.

Professor Troels Lillebæk kommenterer: Interessant systematisk review i AIDS om udbytte af screening for tuberkulose infektion (TBI) blandt personer, der lever med HIV (PLHIV) i tuberkulose lav-incidens lande (som Danmark) . Inddraget i alt 51 undersøgelser med 65.930 PLHIV hvoraf 12 % havde en positiv LTBI-test, som var stærkt relateret til oprindelsesland og eksponering for TB ).


Kalender [1]
24. marts, København
Nyt fra tidsskrifterne [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?

Infection
18.03.2025
. Purposes. A leading cause of death from infectious diseases worldwide is tuberculosis (TB), and it often arises from latent infection. New diagnostic tests for latent tuberculosis infection (LTBI) are needed. Therefore, this study aimed to identify novel biomarker signatures in whole human blood to distinguish between active tuberculosis (ATB) and LTBI. . Methods.
International Journal of Infectious Diseases
18.03.2025
World TB Day is observed annually on March 24th to raise awareness of tuberculosis (TB), a preventable and treatable disease [1]. Despite being treatable for over 65 years, there are approximately 10.8 million new TB cases annually, predominantly in low- and middle-income countries. Drug-resistant TB significantly contributes to deaths, impacting an estimated 400,000 individuals each year. TB-HIV coinfection remains a major concern, with an estimated 660,000 individuals affected by the dual infection.
BMC Infectious Diseases
17.03.2025
. Background. Tuberculosis (TB) remains a major global health threat. Mass screening effectively detects hidden TB cases and latent tuberculosis infections (LTBI), crucial for prevention. This study aims to use IFN-γ release assay (IGRA) screening in Deqing elderly reveals hidden TB and LTBI cases, explore the risk factors influencing the clustering of LTBI. . Methods.
Tropical Medicine & International Health
15.03.2025
Tropical Medicine &International Health, EarlyView.
Clinical Infectious Diseases
14.03.2025
Abstract . Background . Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. The emergence of resistance to BDQ, a key drug in treating MDR-TB, poses significant threats to TB treatment effectiveness.Methods .
BMJ Open
14.03.2025
. Objective. To determine the cost-effectiveness of the QuantiFERON (QFT) test versus the tuberculin skin test (TST) in diagnosing latent tuberculosis infection (LTBI) in immunocompetent children under 15 years of age who are in contact with active tuberculosis (TB) patients in the context of the Colombian healthcare system. . Design. Health economic evaluation. Decision tree over a horizon of
BMJ Open
14.03.2025
. Objective. To identify the barriers and facilitators of adolescent-friendly tuberculosis (TB) services among adolescents with drug-susceptible TB (DS-TB), as defined by the WHO’s Adolescent-Friendly Services (AFS) framework, in Lima, Peru. . Design. We conducted in-depth interviews using semistructured interview guides.
Proceedings of the National Academy of Sciences
14.03.2025
Proceedings of the National Academy of Sciences, Volume 122, Issue 10, March 2025. SignificanceMycobacterium tuberculosis(Mtb) travels from the lungs of one person through the air to the lungs of another and survives multiple stresses en route, including changes in temperature and in concentrations of oxygen, carbon dioxide, hydrogen .
Tropical Medicine & International Health
13.03.2025
Tropical Medicine &International Health, EarlyView.
International Journal of Infectious Diseases
13.03.2025
Tuberculosis (TB) infection is caused by Mycobacterium tuberculosis complex (MTBC), a closely related group of Mycobacterium species, including Mycobacterium tuberculosis (Mtb) [S1]. TB disease remains a major global health concern, with over 10 million cases and 1.25 million deaths in 2023. An estimated quarter of the world's population, around 2 billion people, has an immune response to Mtb without clinical, microbiological, or radiological signs of TB disease [1].
Infection
12.03.2025
. Purpose. Tuberculosis (TB) remains a leading cause of morbidity and mortality, with 1.3 million deaths in 2022. Extrapulmonary tuberculosis (EPTB) accounts for approximately 20% of all TB cases. We assessed the clinical presentation and challenges during the course of treatment in EPTB patients in a low-incidence setting. . Methods.
PLoS One Infectious Diseases
11.03.2025
… Abdisa, Gudata Imana, Kefyalew Taye, Gonfa Moti, Merob Fufa . Introduction TB is the most frequent opportunistic infection and cause of death among People living with HIV/AIDS. Human immunodeficiency virus-positive individuals are routinely screened for tuberculosis as a means of monitoring efforts to mitigate the consequences of the disease on HIV-positive patients.
BMC Infectious Diseases
11.03.2025
. Background. The bidirectional association of HIV/AIDS and Tuberculosis (TB) presents significant global health challenges. However, the relationship between these dual epidemics and the heterogeneity in their mortality rate patterns have not been properly addressed. Therefore, the aim of this study was to cluster and model the joint trajectories of HIV/AIDS and TB mortality rates from 1990 to 2021 worldwide. . Methods.
BMC Infectious Diseases
11.03.2025
. Objective. Globally, Tuberculosis(TB) with type 2 diabetes mellitus (T2DM) is becoming increasingly serious, especially the emergence of rifampicin-susceptible and isoniazid-resistant tuberculosis (Hr-TB), which increases the difficulty of treatment and the burden of disease.
International Journal of Infectious Diseases
10.03.2025
The global effort to control and eliminate tuberculosis (TB) is being substantially thwarted by the rising type 2 diabetes mellitus (T2DM) pandemic. Of the approximately 10 million people who fell ill with TB in 2023, almost 400,000 cases were attributable to diabetes [1], the majority of whom had T2DM.
International Journal of Infectious Diseases
9.03.2025
Globally, tuberculosis (TB) and HIV are leading infectious causes of morbidity and mortality in their own right and are associated with disproportionately worse outcomes when co-infection occurs. In this review of HIV-associated TB (HIV-TB) in adults, we discuss recent research progress and the challenges towards further reducing incidence and mortality. We present an overview of the epidemiology and discuss current knowledge and ongoing gaps regarding the spectrum of HIV-TB disease in adults.
International Journal of Infectious Diseases
9.03.2025
Globally in 2023, 8.2 million people with a new episode of tuberculosis (TB) were diagnosed and notified.[1] This is the highest number of TB notifications for a single year since the World Health Organization (WHO) started to compile country data on TB in the mid-1990s. However, this number still falls almost three million short of the 10.8 million (95% uncertainty interval 10.1-11.7 million) people estimated to have developed TB in 2023.[1]
Proceedings of the National Academy of Sciences
7.03.2025
Proceedings of the National Academy of Sciences, Volume 122, Issue 9, March 2025. SignificanceThe rise of multidrug-resistant tuberculosis underscores the urgent need for novel tuberculosis (TB) drugs while prioritizing synergistic drug combinations. Multiple studies have delineated bacterial pathways influencing antibiotic efficacy .
Lancet
7.03.2025
Tuberculosis is a leading cause of death globally. Given the airborne transmission of tuberculosis, anybody can be infected, but people in high-incidence settings are more exposed. Risk of progression to disease is higher in the first years after infection, and in people with undernourishment, immunosuppression, or who smoke, drink alcohol, or have diabetes. Although cough, fever, and weight loss are hallmark symptoms, people with tuberculosis can be asymptomatic, so a high index of suspicion is required.
Aktuelle smitsomme sygdomme [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?

ProMED
13.03.2025
. . . TUBERCULOSIS - ECUADOR (02): PRISON, FATALITIES, REQUEST FOR. INFORMATION. ************************************************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Mon 10 Mar 2025 . Source: El Universo, Ecuador [in Spanish, machine trans., edited] .
Medscape Infectious Diseases
7.03.2025
The Trump administration's decision to pause U.S. foreign aid would undo progress made in containing tuberculosis (TB) infections across low- and middle-income countries,. . Reuters Health Information
ProMED
21.02.2025
. . . TUBERCULOSIS - COLOMBIA: (SANTANDER) PRISON. *******************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Wed 19 Feb 2025 . Source: El Frente [in Spanish, machine trans., edited] . elfrente.com.co/ya-son-79-los-infectados-de-tuberculosis-en-la-modelo/ . . . There are already 79 people infected with tuberculosis in La Modelo. prison .
ProMED
12.02.2025
. . . TUBERCULOSIS - INDIA (04): (MAHARASHTRA) SCREENING CAMPAIGN. ***********************************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Mon 10 Feb 2025 14:44 IST . Source: The Indian Express [edited] . indianexpress.com/article/cities/pune/tuberculosis-elimination-campaign-maharashtra-new-cases-9828064/ . . .
ProMED
9.02.2025
. . . TUBERCULOSIS - INDIA (03): SCREENING CAMPAIGN UPDATE. ****************************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Fri 7 Feb 2025 06:19 IST . Source: The New Indian Express [edited] . www.newindianexpress.com/nation/2025/Feb/07/159-lakh-new-tb-patients-identified-since-launch-of-intensive-campaign-union-health-minister-nadda . .
ProMED
8.02.2025
. . . TUBERCULOSIS - INDIA (02): (UTTAR PRADESH) SCREENING CAMPAIGN. *************************************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Tue 4 Feb 2025 . Source: The Times of India (TOI), Times News Network (TNN) [edited] . timesofindia.indiatimes.com/city/lucknow/over-53000-new-tb-cases-found-in-up/articleshow/117895009.cms . . .
ProMED
8.02.2025
. . . TUBERCULOSIS - ISRAEL: CHILDCARE CLUSTER. ****************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Fri 7 Feb 2025 08:26 IST . Source: Israel National News [edited] . www.israelnationalnews.com/news/403558 . . . Five children have been diagnosedwith tuberculosis in the central.
ProMED
4.02.2025
. . . TUBERCULOSIS - USA (04): (ALASKA). *********************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Mon 3 Feb 2025 . Source: Alaska Beacon [edited] . alaskabeacon.com/2025/02/03/alaskas-tuberculosis-rate-remains-elevated-preliminary-figures-show/ . . . Alaska's tuberculosis rate remains elevated, preliminary figures show .
ProMED
3.02.2025
. . . TUBERCULOSIS - USA (03): (MICHIGAN, CALIFORNIA) HIGH SCHOOL EXPOSURES. *********************************************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . [1] Michigan (Kalamazoo County) . Date: Fri 31 Jan 2025 . Source: WWMT [edited] .
ProMED
31.01.2025
. . . TUBERCULOSIS - UK: 2024 INCREASE, UKHSA. ***************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Thu 30 Jan 2025 . Source: UK Health Security Agency [edited] . www.gov.uk/government/news/tuberculosis-cases-in-england-continued-to-increase-in-2024 . . . The latest provisional annual data for 2024 from the UK Health.
ProMED
30.01.2025
. . . TUBERCULOSIS - USA (02): (KANSAS). *********************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . [1] Kansas Department of Health and Environment . Date: Fri 24 Jan 2025 . Source: Kansas Department of Health and Environment [edited] . www.kdhe.ks.gov/2242/Tuberculosis-Outbreaks . . . Kansas City Area TB Outbreak . ------------------------- .
Medscape Infectious Diseases
29.01.2025
Public official says current TB outbreak is largest since the CDC began tracking in 1950. . Medscape Medical News
ProMED
28.01.2025
. . . TUBERCULOSIS - ECUADOR: PRISON. ******************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Thu 16 Jan 2025 09:29 CST . Source: Prensa Latina [in Spanish, machine trans., edited] . www.prensa-latina.cu/2025/01/16/advierten-de-posible-epidemia-en-mayor-prision-de-ecuador/ . . . The Permanent Committee for the Defense of Human Rights in Ecuador.
ProMED
26.01.2025
. . . TUBERCULOSIS - USA: (KANSAS) INCREASED CASES, REQUEST FOR INFORMATION. *********************************************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Sat 25 Jan 2025 . Source: The Topeka Capital-Journal [edited] .
ProMED
15.01.2025
. . . TUBERCULOSIS - KENYA: VACCINE SHORTAGE. **************************************. A ProMED-mail post. www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases. www.isid.org . Date: Tue 14 Jan 2025 . Source: The Standard [edited] . www.standardmedia.co.ke/health/health-science/article/2001509534/shortage-of-tb-vaccine-hits-puts-children-at-risk . . . An acute shortage of the essential tuberculosis (TB) vaccine has hit.
Medscape Infectious Diseases
19.12.2024
Corticosteroids had no effect on mortality rates or serious adverse events in patients with HIV and tuberculosis, showed a recent meta-analysis. . Medscape Medical News
Medscape Infectious Diseases
31.10.2024
Tuberculosis replaced COVID-19 to become the top cause for infectious disease-related deaths in 2023, according to a World Health Organization report published on Tuesday,. . Reuters Health Information
Eurosurveillance latest updates
12.07.2024
This report documents the case of a Ukrainian patient infected with an extensively drug-resistant (XDR) lineage 2 Mycobacterium tuberculosis strain harbouring the rifampicin resistance mutation RpoB I491F. This mutation is not detected by routine molecular WHO-recommended rapid diagnostics, complicating the detection and treatment of these strains.
Eurosurveillance latest updates
14.06.2024
. Background. Denmark possesses an exceptional historical data collection on tuberculosis (TB) from 1876 to the present, providing a unique opportunity to assess TB epidemiology over 147 years in Denmark. . . Aim. Our aim was to describe the TB disease burden in Denmark in relation to historical events, living conditions and health interventions during the past 147 years. . . Methods.
Morbidity and Mortality Weekly Report (MMWR)
4.06.2024
This report provides an update on progress toward tuberculosis (TB) elimination and TB program performance during 2016-2022.

DSI på

Følg os på linkedin.com/company/dansk-selskab-for-infektionsmedicin

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2025 Dansk Selskab for Infektionsmedicin

CVR: 33634307

infmed.dk
Version: 2.2.1
PHP version: 8.0.30
Design: Christian Philip Fischer
Side indlæst på 1.19 s

Cookies og privatliv